Jakafi 15 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FX7Z2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $54,488
Award facts
- Contract value 100% obligated
- $54,487.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $54,487.52 to DMS Pharmaceutical Group Inc. for 60-count tablets of Jakafi 15 mg, with an ultimate completion date of September 19, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.9 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide.
Jakafi (ruxolitinib) is a prescription medication used primarily to treat myelofibrosis and polycythemia vera, conditions affecting blood cell production. As a strategic supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group leverages its status as a woman-owned small business to compete effectively in DLA procurement markets while maintaining a robust portfolio of branded and generic prescription drugs, biologics, and medical consumables. The company's consistent performance delivering specialized pharmaceutical products to military health facilities demonstrates its critical role in supporting the Department of Defense's healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FX7Z2?
SPE2DB25FX7Z2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 18, 2025.
How much is contract SPE2DB25FX7Z2 worth?
The government has obligated $54,488 on SPE2DB25FX7Z2.
Is contract SPE2DB25FX7Z2 an order under another contract?
Yes. SPE2DB25FX7Z2 is a delivery order under SPE2DB20D9354, an indefinite delivery contract.
Was contract SPE2DB25FX7Z2 competed?
The extent of competition for SPE2DB25FX7Z2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award